For example, point mutations and genomic gains of the TNFR2 gene (TNFRSF1B) enhancing the activation of the non-canonical NF-κB signaling pathway have been described in 18% of patients with recurrent CTCL, for both mycosis fungoides and Sézary syndrome (Ungewickell et al., 2015). The gene discussed is TNFRSF1B; the disease is Sezary syndrome.